急诊阿替普酶静脉溶栓联合依达拉奉治疗急性脑梗死疗效观察  

The clinical efficacy of Alteplase for emergent thrombolysis combined with Edaravone for treating acute cerebral infarction

作　　者：李国明[1] 彭玉维[1] 邹剑 LI Guo-ming;PENG Yu-wei;ZOU Jian(Department of Emergency,Central Hospital of Jiangmen,Guangdong 529030,China)

机构地区：[1]江门市中心医院急诊科,广东江门529030

出　　处：《中国处方药》2020年第4期81-82,共2页Journal of China Prescription Drug

摘　　要：目的观察急诊阿替普酶静脉溶栓联合依达拉奉治疗急性脑梗死的临床效果。方法将56例急性脑梗死患者随机分为两组,对照组26例,常规治疗并进行急诊阿替普酶溶栓;试验组30例,在对照组的基础上给予依达拉奉治疗。在溶栓前、治疗后第3、7天计算两组神经功能缺损评分(NIHSS),并检测静脉血C反应蛋白(CRP)、D-二聚体水平,用于评估两组治疗效果。结果试验组治疗后第3、7天NIHSS评分、CRP、D-二聚体水平明显低于对照组,差异有统计学意义(P <0.05)。结论急诊阿替普酶静脉溶栓联合依达拉奉治疗急性脑梗死效果较好,有较高的临床价值。Objective To observe the clinical efficacy of alteplase for emergent thrombolysis combined with edaravone in treating acute cerebral infarction. Methods 56 patients with acute cerebral infarction from January 2018 to December 2018 were retrospectively reviewed. The control(26 cases) group was treated with alteplase for emergent thrombolysis;The experimental group was treated with alteplase for emergent thrombolysis combined with edaravone. The neurological deficits in all patients were assessed by National Institute of Health Stroke Scale(NIHSS) before treatment and on 3 days and 7 days after admission;the levels of serum D-dimer and C-reactive protein(CRP) were measured respectively before treatment and on 3 days and 7 days after admission. Results The NIHSS scores, D-dimer and CRP in the experimental group were lower than those in the control group on 3 days and 7 days after admission,the difference between two groups is significant(P < 0.05).Conclusion The clinical efficacy was good by using alteplase for emergent thrombolysis combined with edaravone in treating acute cerebral infarction.

关 键 词：阿替普酶 静脉溶栓 依达拉奉 急性脑梗死 疗效 

分 类 号：R743.3[医药卫生—神经病学与精神病学]